Becotatug clinical trials
Also written JMT101.
How each study uses becotatug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the becotatug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2024 | 4 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
Shanghai JMT-Bio Inc. (10) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · Peking University (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test becotatug, phase 3 first.
- Mar 2027JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsPhase 3 · Shanghai JMT-Bio Inc.
- Jun 2027The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal CancerPhase 3 · Shanghai JMT-Bio Inc.
Studies
Open first, then newest update. How each study uses becotatug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCCNot yet recruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06989671Written as JMT101
- The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal CancerNot yet recruitingPhase 3Shanghai JMT-Bio Inc.NCT07134205Written as JMT101
- JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT06892431Written as JMT101 injection
- A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsRecruitingPhase 3Shanghai JMT-Bio Inc.NCT06735391Written as JMT101
- JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsNot yet recruitingPhase 3Shanghai JMT-Bio Inc.NCT06380348Written as JMT101 Injection
- Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerNot yet recruitingPhase 2/3Shanghai JMT-Bio Inc.NCT06319313Written as JMT101
- A Study of JMT101 in Patients With Metastatic Colorectal CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT06089330Written as JMT101
- JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common MutationsActive, not recruitingPhase 2Shanghai JMT-Bio Inc.NCT06391944Written as JMT101 Injection
- JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard TherapyStatus unknownPhase 1Peking UniversityNCT05164848Written as JMT101
- Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerStatus unknownPhase 2Shanghai JMT-Bio Inc.NCT05132777Written as JMT101
- Efficacy and Safety of JMT101 in Patients With Advanced Solid TumorStatus unknownPhase 1Shanghai JMT-Bio Inc.NCT04689100Written as JMT101
- Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung CancerStatus unknownPhase 1Shanghai JMT-Bio Inc.NCT04448379Written as JMT101
Codes
What other systems call becotatug · ClinicalTrials.gg INT015819
- UNII (FDA) 981YA69AO3BECOTATUGOne source FDA
- NCI Thesaurus C178313BecotatugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 981YA69AO3 | BECOTATUG | One source FDA |
| NCI Thesaurus | C178313 | Becotatug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.